Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is a publicly traded Healthcare sector company. As of October 29, 2026, AMLX trades at $28.35 with a market cap of $3.55B and a P/E ratio of -18.11. AMLX moved +1.00% today. Year to date, AMLX is +145.80%; over the trailing twelve months it is +96.02%. Its 52-week range spans $3.11 to $41.14. Analyst consensus is strong buy with an average price target of $46.63. Rallies surfaces AMLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest AMLX news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $28.35 |
| Market Cap | $3.55B |
| P/E Ratio | -18.11 |
| EPS | $-1.53 |
| Dividend Yield | 0.42% |
| 52-Week High | $41.14 |
| 52-Week Low | $3.11 |
| Volume | 7.49K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-144.74M |
| Gross Margin | 0.00% |
9 analysts cover AMLX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $46.63.